Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2

ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today reported on the clinical progress of its novel antiviral candidate, ensovibep,...

read more

New Spanish clinical data from Proclarix® together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 36th Annual European Urology Congress

Zurich-Schlieren, Switzerland, July 7, 2021. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that the group of Prof. J Morote Robles from the Vall d’Hebron University Hospital in Barcelona, Spain will present their clinical study results of Proclarix® in combination with MRI for improved prostate...

read more

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

Schlieren (Zurich), Switzerland, 22, 2021 – Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron...

read more